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ABSTRACT 
Objective 
To test the current progressive multifocal leukoencephalopathy (PML) diagnostic criteria by applying 
them to patients previously diagnosed with natalizumab-associated (NTZ) PML in a real-world clinical 
setting. 
Methods 
Patients from the Dutch-Belgian NTZ-PML cohort (n=28) were reviewed at the time of first diagnostic 
work-up and during follow-up, using the PML diagnostic criteria as proposed in a consensus 
statement from the American Academy of Neurology (AAN). 
Results 
At first diagnostic work-up, 18 patients (64.3%) met the criteria for high diagnostic certainty for PML 
(“definite PML” or “probable PML”). During follow-up, this increased to 20 patients (71.4%) as JCV 
DNA was detected in CSF of two additional patients. Nonetheless, 28.6% of patients were still 
classified as “possible PML” or “not PML” (6 [21.5%] and 2 [7.1%] patients, respectively) despite a 
very high suspicion for PML based on lesion evolution and signs of PML-immune reconstitution 
inflammatory syndrome on MRI, and development of compatible symptoms. 
Conclusions 
The current case definition of PML has low sensitivity for diagnosis of NTZ-PML in a real-world clinical 
setting in which MRI is frequently used for PML screening. This may delay diagnosis and appropriate 
management of PML, and may complicate a valid estimation of PML incidence during NTZ therapy.  
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INTRODUCTION 
Progressive multifocal leukoencephalopathy (PML) may complicate treatment with natalizumab 
(NTZ) in patients with multiple sclerosis (MS),1 and early diagnosis improves functional outcome and 
survival.2 Criteria for the diagnosis of PML were published in a consensus statement from the 
American Academy of Neurology (AAN) Neuroinfectious Disease Section, comprising four categories 
(definite, probable, possible, and not PML) based on the presence of three diagnostic features: 
clinical symptoms suggestive of PML, imaging findings suggestive of PML, and detection of JC virus 
DNA in CSF by PCR (CSF JCV PCR).3  
Enhanced pharmacovigilance by frequent MRI screening in high-risk patients leads to early detection 
of MRI lesions suggestive of PML, even before the onset of symptoms.4 In addition, JCV DNA can be 
undetectable by PCR, especially in those patients with low PML lesion volumes on MRI.5 6 However, 
absence of symptoms and a negative PCR hamper the formal diagnosis of PML, even when imaging is 
highly suggestive of PML. This study aims to investigate the performance of the PML diagnostic 
criteria in our cohort of NTZ treated patients with PML (NTZ-PML) in a routine clinical 
pharmacovigilance setting, to determine to what extent these limitations affect sensitivity of these 
criteria. 
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METHODS 
Study design and patient selection 
Patients were recruited from the Dutch-Belgian NTZ-PML cohort, which comprises patients treated at 
our center (n=5), or referred to us for a second opinion or research purposes (n=23). All were 
considered to have NTZ-PML by the treating neurologist and the authors based on one of the two 
following criteria:  
(a) A positive JCV PCR in the CSF in combination with lesions on MRI suggestive of PML, irrespective 
of PML symptoms.  
(b) In the absence of a positive CSF JCV PCR, the presence of all four following features:  
1. a high risk of developing PML, i.e., positive anti-JCV serostatus and NTZ treatment duration 
>12 months; 
2. absence of MS disease activity prior to PML suspicion; 
3. MRI lesions highly suggestive of PML with lesion characteristics as previously reported and 
not suggestive of other diseases,7-12 as judged by an experienced neuroradiologist (MPW); 
4. lesion evolution on follow-up MRI suggestive of PML, including development of immune 
reconstitution inflammatory syndrome (IRIS), characterized by contrast enhancement within 
the PML lesion (or outside of the PML lesion following a perivascular pattern) as previously 
described.13 
Fulfillment of criterion b is exemplified for one representative case in figure 1.  
 
PML diagnostic criteria 
We retrospectively collected data on the presence of symptoms, MRI lesions suggestive of PML,7-12 
CSF JCV PCR results, and histopathological findings. All patients were classified according to the PML 
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diagnostic criteria (table 1). Classification was performed at first diagnostic work-up for PML, and at 
the last time point available during the follow-up. Fisher’s exact test and one-way ANOVA were used 
to analyze differences in age, gender and NTZ treatment duration between the diagnostic categories. 
JCV PCR was performed in different laboratories: NIH (NINDS/NIH, Bethesda, MD, USA) or Focus 
laboratories (Focus Diagnostics Inc., Cypress, CA, USA) (21 patients), both with a reported current 
lower limit of detection (LLOD) of 10 copies/ml; Unilabs laboratory, Copenhagen, Denmark (4 
patients), current LLOD of 11 copies/ml and three laboratories without a reported LLOD (but with 
positive PCR results): the Institute for Virology, Heinrich Heine University, Düsseldorf, Germany (1 
patients) and two local hospital laboratories (2 patients). 
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RESULTS 
Of the 28 included patients, 17 (60.7%) were female. At first diagnostic work-up for PML, median NTZ 
treatment duration was 50.5 months (interquartile range (IQR) 36-58), median age was 43.5 years 
(IQR 40-52), and median interval between MRI and CSF collection was 1 day (IQR 1-5). 
Table 1 presents numbers and percentages of patients per diagnostic category, both at first 
diagnostic work-up and at last follow-up. At first diagnostic work-up 18 (64.3%) patients met the 
criteria for “definite PML” or “probable PML” according to the PML diagnostic criteria, generally 
considered as confirmed PML. Nonetheless, at that time, 10 patients who we considered to have 
PML did not meet these criteria.  
Possible case descriptions PML diagnostic criteria 
Clinical 
features 
MRI 
findings 
CSF JCV 
PCR 
Diagnostic 
category 
Number of patients meeting 
criteria (%) 
   At 1st 
diagnostic 
work-up 
At last 
follow-up 
+ + + Definite 10 (35.7) 18 (64.3) 
+ - + 
Probable 
0 0 
- + + 8 (28.6) 2 (7.1) 
+ + - or ND 
Possible 
5 (17.9) 6 (21.5) 
- - + 0 0 
+ - - 
Not PML 
0 0 
- + - 5 (17.9) 2 (7.1) 
- - - 0 0 
 
Table 1. Categories of diagnostic certainty for PML diagnosis according to the PML diagnostic 
criteria,3 and its application to the Dutch-Belgian NTZ-PML cohort. ND = not determined. Percentages 
were rounded and may not total to 100%. 
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Follow-up data were available for at least 6 months after PML diagnosis in all patients. The online 
supplementary figure presents the changes in diagnostic categories during follow-up based on 
development of symptoms and the results of repeated CSF JCV PCR. In two patients with a previously 
negative PCR, the PCR in an additionally  collected CSF sample was positive. Nine patients, 
asymptomatic for PML at first diagnostic workup, developed PML symptoms later on. Eight patients 
did not exceed the criteria for “possible PML” or “not PML” during follow-up. Seven of them 
developed PML-IRIS following immune reconstitution. No significant differences were found between 
the diagnostic categories in terms of age, gender or NTZ treatment duration. 
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DISCUSSION 
Our study demonstrates that the criteria for diagnosis of PML may not be sufficiently sensitive when 
applied in a real-world clinical setting with early PML lesion detection by MRI. As a result, a 
significant proportion of patients (10 patients (36%) in our cohort) may have undetectable JCV DNA 
at first PML suspicion and will not be classified as “definite PML” or “probable PML”. This may lead to 
a certain degree of diagnostic uncertainty, particularly in centers with a low level of experience in 
PML diagnosis. In this case, this might delay appropriate therapeutic interventions and patient 
management, possibly leading to an unfavorable outcome. Even during follow-up, a majority of these 
patients (8 of the 10 in our cohort) may still be categorized as “possible PML” or “not PML”, and may 
thus be registered with the regulatory authorities as ‘high suspect cases’ rather than ‘confirmed 
cases’, impacting official incidence numbers of PML. 
Our study is limited by the use of a retrospective dataset and thus clinical assessment, MRI, PCR 
procedures, and the number of CSF collections in patients with a negative PCR were not 
standardized. However, this reflects real world clinical practice in MS pharmacovigilance. The fact 
that 8 patients never had a positive JCV PCR at the end of follow-up might be considered as a 
limitation. However, we do consider them to have PML based on the MRI lesion characteristics at 
baseline and evolution of these lesions during follow-up, only fitting the diagnosis of PML and not 
suggestive of any other disease according to the NTZ-PML lesion characteristics reported in the 
literature.7-13 Furthermore, following immune reconstitution 7 of these 8 patients developed clinical 
symptoms and MRI findings compatible with PML-IRIS.13 Finally, all 8 patients had high a priori risk 
for PML (inclusion criterion 1).  
It is important to note that false-positive suspicion of PML based on MRI may also negatively impact 
treatment decisions, such as insufficient immunosuppression in a patient with active MS. There is a 
need to improve the sensitivity of the PCR analysis (e.g. by enhanced pre-analytic CSF 
standardization), and of the MRI criteria for PML diagnosis. Furthermore, analysis of intrathecally 
produced antibody responses to JCV14 15 may lead to indirect proof of JC viral etiology. 
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Meanwhile, in conclusion for clinical practice, PML suspicion based on MRI may require repeated CSF 
collections to confirm PML diagnosis, and if suspicion persists despite repetitively undetectable JCV 
DNA from CSF, counseling with regards to brain biopsy should be considered. In our view, and in 
accordance with the principle “primum non nocere”, if presence of JCV DNA as causative agent can 
neither be proven nor ruled out, patients highly suspected of having PML based on MRI should be 
treated as PML, in particular if risk factors (e.g. long-term therapy with natalizumab, JCV 
seropositive) are present. Current PML diagnostic criteria for MS pharmacovigilance purposes should 
be revised considering these aspects - aspects that only recently became relevant with introducing 
MRI for screening in patients at risk of developing PML. 
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FIGURE LEGENDS 
Figure 1. 
Title: MR imaging of a NTZ-PML patient included in this study based on inclusion criterion b. 
Legend: Axial fluid attenuation inversion recovery (FLAIR; left column), T2-weighted (middle column) 
and contrast-enhanced T1-weighted (right column) images of a patient with a high risk for PML 
development (positive anti-JC virus serostatus and long-term natalizumab treatment (>48 infusions)), 
no MS disease activity during natalizumab treatment, and lesions on MRI highly suggestive of PML. 
Multiple FLAIR and T2 hyperintense lesions subcortical, cortical and in the deep white matter, 
without enhancement after gadolinium (D – F; closed arrowheads). In retrospect, one lesion was 
already visible four months earlier (A – C; closed arrowhead). CSF was collected three times: on the 
day of MRI D – F, and one week and one month later. In all samples JC virus PCR was negative (local 
hospital lab and Focus laboratories (Focus Diagnostics Inc., Cypress, CA, USA)). Natalizumab was 
stopped and plasma exchange was performed. Two and a half months later, the patient’s condition 
deteriorated with a left sided paralysis and lowered consciousness. Follow-up MRI (G – I) showed 
progression of the existing lesions and development of new lesions (closed arrowheads), with a  
patchy contrast enhancement in lesion borders (open arrowheads), in accordance with immune 
reconstitution inflammatory syndrome (PML-IRIS). The patient met the criteria for “possible PML” 
according to the PML diagnostic criteria at this stage. 
